Certolizumab pegol.

Published

Journal Article (Review)

Certolizumab pegol (Cimzia(®)) is currently the only PEGylated anti-TNFα biologic approved for the treatment of rheumatoid arthritis and Crohn disease. The product, developed by UCB, is a humanized antigen-binding fragment (Fab') of a monoclonal antibody that has been conjugated to polyethylene glycol. Certolizumab pegol was approved as a treatment for rheumatoid arthritis in the EU, US and Canada in 2009, and as a treatment for Crohn disease in Switzerland in 2007 and the US in 2008. Certolizumab pegol is entering into an increasingly competitive marketplace, especially in rheumatoid arthritis, but clinical data demonstrate benefits across a range of clinical, radiographic and patient reported outcomes.

Full Text

Duke Authors

Cited Authors

  • Goel, N; Stephens, S

Published Date

  • March 2010

Published In

Volume / Issue

  • 2 / 2

Start / End Page

  • 137 - 147

PubMed ID

  • 20190560

Pubmed Central ID

  • 20190560

Electronic International Standard Serial Number (EISSN)

  • 1942-0870

Digital Object Identifier (DOI)

  • 10.4161/mabs.2.2.11271

Language

  • eng

Conference Location

  • United States